Next set of events in order28 Sep 2025 09:28
Based on the latest updates from Blencowe Resources (#BRES), the near-term news flow for the Orom-Cross graphite project in Uganda is indeed shaping up around additional assay results from the recently completed Stage 7 drilling program, followed by a JORC resource upgrade, and culminating in the Definitive Feasibility Study (DFS) delivery.
### Quick Recap of Recent Momentum
- The company just announced confirmation of high-grade graphite extensions at both the Camp Lode and Northern Syncline areas on September 25, 2025. These results build on the Stage 7 drilling (completed in July), which targeted resource expansion and de-risking.
- All ongoing data from this program is being integrated directly into the JORC upgrade and DFS.
### Upcoming Catalysts in Sequence
1. More Assays/Drilling Results: Expect additional batches of assay results in the coming weeks. The full Stage 7 dataset (over 6,000m drilled) is still being processed, with these extensions already validating deeper and wider mineralization. This should provide further upside to resource tonnage and grade, acting as the immediate next trigger.
2. JORC Resource Upgrade: Once all assays are compiled (likely Q4 2025, post-drilling results), the company plans a material upgrade to the JORC-compliant resource estimate. This is expected to boost contained graphite tonnes significantly, supporting a larger-scale mine plan and enhancing project economics ahead of the DFS.
3. DFS Completion: Targeted for Q4 2025 (potentially as early as October/November). Major DFS workstreams—like infrastructure, metallurgy, and environmental studies—are already wrapped up, leaving mainly integration of the drilling data. This will unlock post-tax NPV estimates (building on the prior PFS's US$482M figure) and pave the way for project financing and potential offtake deals in early 2026.
This pipeline positions #BRES for a strong rerating as the graphite market heats up for EV demand. The recent £1.12M raise in September fully funds through DFS and into financing talks. Keep an eye on RNS announcements for the next assay drop—could be any day now. DYOR, as always.